文献速递膀胱癌与上尿路尿路上皮癌

原发性与继发性肌层浸润性膀胱癌三联疗法肿瘤学结局比较

Oncological Outcomes of Trimodal Therapy in Primary Versus Secondary Muscle-invasive Bladder Cancer: A Multicenter Retrospective Study.
PubMed 文献 · Eur Urol Oncol · 2026-01-22

这项多中心回顾性研究比较了原发性与继发性肌层浸润性膀胱癌接受保膀胱三联疗法(TMT)的结局。共纳入294例患者(原发234例,继发60例),中位年龄77岁。调整协变量后,继发性膀胱癌与复发风险(HR 1.35,95%CI 0.85-2.13)和癌症特异性死亡风险(HR 0.88,95%CI 0.44-1.76)升高无关,但总生存期较低。既往非肌层浸润性膀胱癌病史不应妨碍合适患者选择保膀胱治疗。

要点

  • 继发性MIBC与原发性MIBC接受TMT后复发和癌症特异性死亡风险无显著差异。
  • 继发性MIBC患者的总生存期低于原发性MIBC患者。
  • 既往NMIBC病史不应排除合适患者接受保膀胱三联治疗。

核心结论

  • TMT后原发性和继发性MIBC的肿瘤学结局总体相似,但继发性患者总生存期较低。
  • 既往NMIBC病史不应妨碍在合适选择的患者中考虑保膀胱治疗。

研究设计与样本

  • 多中心回顾性研究,纳入接受根治性TMT的MIBC患者,要求分期≥T2且完成TMT未中断。
  • 共294例患者,其中原发性MIBC 234例,继发性MIBC 60例;中位年龄77岁。
  • 原发性MIBC定义为诊断时≥T2;继发性MIBC定义为既往NMIBC后进展。
  • 主要终点为无复发生存期;次要终点包括无转移生存期、癌症特异性生存期(CSS)、总生存期和治疗相关毒性。
  • 采用Kaplan-Meier法和多变量Cox回归评估生存。

主要发现

  • 原发性MIBC中位随访34个月,继发性MIBC中位随访24个月。
  • 3年CSS率原发性MIBC为78%,继发性MIBC为79%。
  • 调整临床协变量后,继发性MIBC与复发风险增加无关(HR 1.35,95%CI 0.85-2.13)。
  • 继发性MIBC与癌症特异性死亡风险增加无关(HR 0.88,95%CI 0.44-1.76)。
  • 毒性大多为1-2级,≥3级事件罕见。

临床怎么用

  • 对于合适的MIBC患者,既往NMIBC病史不应作为排除保膀胱TMT的理由。
  • 继发性MIBC患者接受TMT后总生存期较低,需综合评估并加强随访。

局限性

  • 回顾性研究设计。
  • 继发性MIBC亚组样本量较小。
  • 随访时间相对较短。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Muscle-invasive bladder cancer (MIBC) may present de novo (primary MIBC [pMIBC]) or progress from non-muscle-invasive disease (secondary MIBC [sMIBC]). While sMIBC has been associated with adverse outcomes after radical cystectomy, its prognostic impact in patients undergoing trimodal therapy (TMT) is unclear. We aimed to compare the outcomes between pMIBC and sMIBC in a multicenter cohort treated with bladder-preserving TMT. METHODS: We conducted a retrospective study including patients with MIBC treated with curative-intent TMT. Eligible patients had stage ≥T2 disease and completed TMT without discontinuation. Patients were classified as those having pMIBC (≥T2 at diagnosis) or sMIBC (progression after prior non-muscle-invasive bladder cancer [NMIBC]). The primary endpoint was recurrence-free survival; the secondary endpoints were metastasis-free survival, cancer-specific survival (CSS), overall survival, and treatment-related toxicity. Survival was assessed using Kaplan-Meier methods and multivariable Cox regression. KEY FINDINGS AND LIMITATIONS: Among 294 patients (234 with pMIBC and 60 with sMIBC), the median age was 77 yr. The median follow-up was 34 mo for pMIBC and 24 mo for sMIBC. The 3-yr CSS rate was 78% for pMIBC and 79% for sMIBC. After adjustment for clinical covariates, sMIBC was not associated with an increased risk of recurrence (hazard ratio [HR] 1.35, 95% confidence interval [CI] 0.85-2.13) and cancer-specific death (HR 0.88, 95% CI 0.44-1.76). Toxicities were mostly of grade 1-2; grade ≥3 events were rare. Limitations include the retrospective design, a smaller sMIBC subgroup, and a relatively short follow-up. CONCLUSIONS AND CLINICAL IMPLICATIONS: Outcomes after TMT were broadly similar between pMIBC and sMIBC, although overall survival was lower in patients with secondary disease. A prior NMIBC history should therefore not preclude consideration of bladder-preserving therapy in appropriately selected patients.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Mezepo G, Khene ZE, Boustani J, et al. Oncological Outcomes of Trimodal Therapy in Primary Versus Secondary Muscle-invasive Bladder Cancer: A Multicenter Retrospective Study. Eur Urol Oncol. 2026. PMID: 41577610. doi:10.1016/j.euo.2025.12.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。